About: Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Article
Is Part Of	http://hub.abes.fr/oup/periodical/brheum/2008/volume_47/issue_10/w
Subject	Letters to the Editor MATTERS ARISING
Title	Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
has manifestation of work	http://hub.abes.fr/oup/periodical/brheum/2008/volume_47/issue_10/101093rheumatologyken326/m/web http://hub.abes.fr/oup/periodical/brheum/2008/volume_47/issue_10/101093rheumatologyken326/m/print
related by	http://hub.abes.fr/oup/periodical/brheum/2008/volume_47/issue_10/101093rheumatologyken326/authorship/1 http://hub.abes.fr/oup/periodical/brheum/2008/volume_47/issue_10/101093rheumatologyken326/authorship/2 http://hub.abes.fr/oup/periodical/brheum/2008/volume_47/issue_10/101093rheumatologyken326/authorship/3
Author	Bansback N. Chilcott J. Wailoo A.
article type	letter
publisher identifier	ken326
is part of this journal	Rheumatology

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata